Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Raffeld Website

Mark Raffeld, M.D.

Selected Publications

1)  Venkataraman G, Song JY, Tzankov A, Dirnhofer S, Heinze G, Kohl M, Traverse-Glehen A, Eberle FC, Hanson JC, Raffeld MA, Pittaluga S, Jaffe ES.
Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival.
Blood. 121: 1795-804, 2013.
2)  Huppmann AR, Roullet MR, Raffeld M, Jaffe ES.
Angioimmunoblastic T-cell lymphoma partially obscured by an Epstein-Barr virus-negative clonal plasma cell proliferation.
J. Clin. Oncol. 31: e28-30, 2013.
3)  Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma.
Clin. Cancer Res. 19: 2048-60, 2013.
4)  Venkataraman G, Uldrick TS, Aleman K, O'Mahony D, Karcher DS, Steinberg SM, Raffeld MA, Marshall V, Whitby D, Little RF, Yarchoan R, Pittaluga S, Maric I.
Bone Marrow Findings in HIV-Positive Patients With Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.
Am. J. Clin. Pathol. 139: 651-61, 2013.
5)  Klion AD, Mejia R, Cowen EW, Dowdell KC, Dunleavy K, Fahle GA, Holland-Thomas N, Maric I, Pittaluga S, Raffeld M, Santos C, Stetler-Stevenson M, Krogmann T, Shatzer AN, Turk SP, Yin Y, Xi L, Prussin C, Cohen JI.
Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome.
Blood. 121: 2364-6, 2013.
6)  Thomas A, Xi L, Carter CA, Rajan A, Khozin S, Szabo E, Dennis PA, Giaccone G, Raffeld M.
Concurrent Molecular Alterations in Tumors with Germ Line Epidermal Growth Factor Receptor T790M Mutations.
Clin Lung Cancer. [Epub ahead of print], 2013.
7)  Liu Q, Salaverria I, Pittaluga S, Jegalian AG, Xi L, Siebert R, Raffeld M, Hewitt SM, Jaffe ES.
Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma.
Am. J. Surg. Pathol. 37: 333-43, 2013.
8)  Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, Liu D, Keyvanfar K, Chapman CM, Chen J, Buggy JJ, Aue G, Tisdale JF, Pérez-Galán P, Wiestner A.
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy.
Leukemia. [Epub ahead of print], 2013.
9)  Fuss IJ, Friend J, Yang Z, He JP, Hooda L, Boyer J, Xi L, Raffeld M, Kleiner DE, Heller T, Strober W.
Nodular regenerative hyperplasia in common variable immunodeficiency.
J. Clin. Immunol. 33: 748-58, 2013.
10)  Nicolae A, Pittaluga S, Venkataraman G, Vijnovich-Baron A, Xi L, Raffeld M, Jaffe ES.
Peripheral T-cell Lymphomas of Follicular T-Helper Cell Derivation With Hodgkin/Reed-Sternberg Cells of B-cell Lineage: Both EBV-positive and EBV-negative Variants Exist.
Am. J. Surg. Pathol. 37: 816-26, 2013.
11)  Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC.
Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia.
Blood. 121: 476-84, 2013.
12)  Huppmann AR, Xi L, Raffeld M, Pittaluga S, Jaffe ES.
Subcutaneous panniculitis-like T-cell lymphoma in the pediatric age group: A lymphoma of low malignant potential.
Pediatr Blood Cancer. 2013.
13)  Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, Quezado M, Smith WI, Jahromi MS, Xekouki P, Szarek E, Walker R, Lasota J, Raffeld M, Klotzle B, Wang Z, Jones L, Zhu YJ, Wang Y, Waterfall J, O'Sullivan M, Bibikova M, Pacak K, Stratakis CA, Janeway KA, Schiffman JD, Fan J, Helman LJ, Meltzer PS.
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor.
Cancer Discov. [Epub ahead of print], 2013.
14)  Tamburrino A, Molinolo AA, Salerno P, Chernock RD, Raffeld M, Xi L, Gutkind JS, Moley JF, Wells SA, Santoro M.
Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases.
Clin. Cancer Res. 18: 3532-40, 2012.
15)  Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ.
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
Blood. 119: 3330-2, 2012.
16)  Tembhare P, Yuan CM, Xi L, Marti G, Raffeld M, Stetler-Stevenson M.
Case study interpretation--Portland: Case 1. Hairy cell leukemia with CLL-like monoclonal B lymphocytosis.
Cytometry B Clin Cytom. 82: 177-9, 2012.
17)  Mills KC, Sangüeza OP, Beaty MW, Raffeld M, Pang CS.
Composite B-cell and T-cell lineage post-transplant lymphoproliferative disorder of the lung with unusual cutaneous manifestations of mycosis fungoides.
Am J Dermatopathol. 34: 220-5, 2012.
18)  Snow AL, Xiao W, Stinson JR, Lu W, Chaigne-Delalande B, Zheng L, Pittaluga S, Matthews HF, Schmitz R, Jhavar S, Kuchen S, Kardava L, Wang W, Lamborn IT, Jing H, Raffeld M, Moir S, Fleisher TA, Staudt LM, Su HC, Lenardo MJ.
Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.
J. Exp. Med. 209: 2247-61, 2012.
19)  Chowdhuri SR, Xi L, Pham TH, Hanson J, Rodriguez-Canales J, Berman A, Rajan A, Giaccone G, Emmert-Buck M, Raffeld M, Filie AC.
EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.
Mod. Pathol. 25: 548-55, 2012.
20)  Eberle FC, Song JY, Xi L, Raffeld M, Harris NL, Wilson WH, Pittaluga S, Jaffe ES.
Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.
Am. J. Surg. Pathol. 36: 716-25, 2012.
21)  Lai JP, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA, Miettinen MM, Lee CC.
NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Mod. Pathol. 25: 854-8, 2012.
22)  Kalra N, Ashai A, Xi L, Zhang J, Avital I, Raffeld M, Hassan R.
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Oncol. Rep. 27: 1794-800, 2012.
23)  Slotta-Huspenina J, Koch I, de Leval L, Keller G, Klier M, Bink K, Kremer M, Raffeld M, Fend F, Quintanilla-Martinez L.
The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.
Haematologica. 97: 1422-30, 2012.
24)  Venkataraman G, Berkowitz J, Morris JC, Janik JE, Raffeld MA, Pittaluga S.
Adult T-cell leukemia/lymphoma with Epstein-Barr virus-positive Hodgkin-like cells.
Hum. Pathol. 42: 1042-6, 2011.
25)  Dojcinov SD, Venkataraman G, Pittaluga S, Wlodarska I, Schrager JA, Raffeld M, Hills RK, Jaffe ES.
Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma.
Blood. 117: 4726-35, 2011.
26)  Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES.
CD15-expressing nodular lymphocyte-predominant Hodgkin lymphoma.
Histopathology. 58: 803-5, 2011.
27)  Harada T, Lopez-Chavez A, Xi L, Raffeld M, Wang Y, Giaccone G.
Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.
Oncogene. 30: 1744-52, 2011.
28)  Shao H, Xi L, Raffeld M, Feldman AL, Ketterling RP, Knudson R, Rodriguez-Canales J, Hanson J, Pittaluga S, Jaffe ES.
Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases.
Mod Pathol. 24: 1421-32, 2011.
29)  Song JY, Eberle FC, Xi L, Raffeld M, Rahma O, Wilson WH, Dunleavy K, Pittaluga S, Jaffe ES.
Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphoma.
Am. J. Surg. Pathol. 35: 767-72, 2011.
30)  Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, Yu Y, Choyke P, Turkbey B, Raffeld M, Xi L, Steinberg SM, Wright JJ, Kummar S, Gutierrez M, Giaccone G.
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Clin. Cancer Res. 17: 1190-9, 2011.
31)  Tembhare P, Yuan CM, Xi L, Morris JC, Liewehr D, Venzon D, Janik JE, Raffeld M, Stetler-Stevenson M.
Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy.
Am. J. Clin. Pathol. 135: 890-900, 2011.
32)  Jegalian AG, Eberle FC, Pack SD, Mirvis M, Raffeld M, Pittaluga S, Jaffe ES.
Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma.
Blood. 118: 2976-84, 2011.
33)  Eberle FC, Salaverria I, Steidl C, Summers TA, Pittaluga S, Neriah SB, Rodriguez-Canales J, Xi L, Ylaya K, Liewehr D, Dunleavy K, Wilson WH, Hewitt SM, Raffeld M, Gascoyne RD, Siebert R, Jaffe ES.
Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations.
Mod Pathol. 24: 1586-97, 2011.
34)  Ward Y, Lake R, Yin JJ, Heger CD, Raffeld M, Goldsmith PK, Merino M, Kelly K.
LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells.
Cancer Res. 71: 7301-11, 2011.
35)  Venkataraman G, Rizzo KA, Chavez JJ, Streubel B, Raffeld M, Jaffe ES, Pittaluga S.
Marginal zone lymphomas involving meningeal dura: possible link to IgG4-related diseases.
Mod. Pathol. 24: 355-66, 2011.
36)  Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G.
Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1{alpha} in Advanced Solid Tumors.
Clin. Cancer Res. 17: 5123-31, 2011.
37)  Hsu AP, Sampaio EP, Khan J, Calvo KR, Lemieux JE, Patel SY, Frucht DM, Vinh DC, Auth RD, Freeman AF, Olivier KN, Uzel G, Zerbe CS, Spalding C, Pittaluga S, Raffeld M, Kuhns DB, Ding L, Paulson ML, Marciano BE, Gea-Banacloche JC, Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM.
Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.
Blood. 118: 2653-5, 2011.
38)  Calvo KR, Vinh DC, Maric I, Wang W, Noel P, Stetler-Stevenson M, Arthur DC, Raffeld M, Dutra A, Pak E, Myung K, Hsu AP, Hickstein DD, Pittaluga S, Holland SM.
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications.
Haematologica. 96: 1221-5, 2011.
39)  Garcia-Herrera A, Song JY, Chuang S, Villamor N, Colomo L, Pittaluga S, Alvaro T, Rozman M, de Anda Gonzalez J, Arrunategui AM, Fernandez E, Gonzalvo E, Estrach T, Colomer D, Raffeld M, Gaulard P, Campo E, Jaffe ES, Martinez A.
Nonhepatosplenic gamma-delta T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation.
Am. J. Surg. Pathol. 35: 1214-25, 2011.
40)  Song JY, Strom T, Raffeld M, Pittaluga S, Jaffe ES.
Peripheral T-cell lymphoma with aberrant expression of CD30, CD15, and CD20.
J. Clin. Oncol. 29: e789-91, 2011.
41)  Niemela JE, Lu L, Fleisher TA, Davis J, Caminha I, Natter M, Beer LA, Dowdell KC, Pittaluga S, Raffeld M, Rao VK, Oliveira JB.
Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.
Blood. 117: 2883-6, 2011.
42)  Maldonado NI, Cabanillas F, Jaffe ES, Raffeld M, Lozada L.
Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.
J. Clin. Oncol. 29: e658-60, 2011.
43)  Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A.
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
Blood. 117: 563-74, 2011.
44)  Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
J. Clin. Oncol. 29: 917-24, 2011.
45)  Zerfas PM, Brinster LR, Starost MF, Burkholder TH, Raffeld M, Eckhaus MA.
Amelanotic Melanoma in a New Zealand White Rabbit (Oryctolagus cuniculus).
Vet. Pathol. 47: 977-81, 2010.
46)  Vinh DC, Patel SY, Uzel G, Anderson VL, Freeman AF, Olivier KN, Spalding C, Hughes S, Pittaluga S, Raffeld M, Sorbara LR, Elloumi HZ, Kuhns DB, Turner ML, Cowen EW, Fink D, Long-Priel D, Hsu AP, Ding L, Paulson ML, Whitney AR, Sampaio EP, Frucht DM, DeLeo FR, Holland SM.
Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia.
Blood. 115: 1519-29, 2010.
47)  Raffeld M, Jaffe ES.
Avidin-biotin labeling of cellular antigens in cryostat-sectioned tissue.
Methods Mol. Biol. 588: 271-9, 2010.
48)  Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, Jaffe ES.
Blastic plasmacytoid dendritic cell neoplasm in the pediatric population: diagnostic features and clinical implications.
Haematologica. 95: 1873-9, 2010.
49)  Anastasov N, Bonzheim I, Rudelius M, Klier M, Dau T, Angermeier D, Duyster J, Pittaluga S, Fend F, Raffeld M, Quintanilla-Martinez L.
C/EBPbeta expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.
Haematologica. 95: 760-7, 2010.
50)  Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES.
EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression.
Am. J. Surg. Pathol. 34: 405-17, 2010.
51)  Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DN, Lanier BJ, Morgan RA, Rosenberg SA.
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19.
Blood. 116: 4099-102, 2010.
52)  Mani H, Climent F, Colomo L, Pittaluga S, Raffeld M, Jaffe ES.
Gall Bladder and Extrahepatic Bile Duct Lymphomas: Clinicopathological Observations and Biological Implications.
Am J Surg Pathol. 34: 1277-86, 2010.
53)  Wang Y, Tan XH, DiGiovanna JJ, Lee CC, Stern JB, Raffeld M, Jaffe ES, Kraemer KH.
Genetic diversity in melanoma metastases from a patient with xeroderma pigmentosum.
J. Invest. Dermatol. 130: 1188-91, 2010.
54)  Krenacs L, Krenacs T, Stelkovics E, Raffeld M.
Heat-induced antigen retrieval for immunohistochemical reactions in routinely processed paraffin sections.
Methods Mol. Biol. 588: 103-19, 2010.
55)  Rizzo KA, Streubel B, Pittaluga S, Chott A, Xi L, Raffeld M, Jaffe ES.
Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR.
Mod. Pathol. 23: 866-73, 2010.
56)  Jin L, Tabe Y, Kojima K, Zhou Y, Pittaluga S, Konopleva M, Miida T, Raffeld M.
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
Cancer Lett. 299: 161-70, 2010.
57)  Roufosse F, Lavareille AD, Schandené L, Cogan E, Georgelas A, Wagner L, Xi L, Raffeld M, Goldman M, Gleich GJ, Klion A.
Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
J Allergy Clin Immunol. 126: 828-35, 2010.
58)  Shao H, Yuan CM, Xi L, Raffeld M, Morris JC, Janik JE, Stetler-Stevenson M.
Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.
Am. J. Clin. Pathol. 133: 592-601, 2010.
59)  Krenacs T, Krenacs L, Raffeld M.
Multiple antigen immunostaining procedures.
Methods Mol. Biol. 588: 281-300, 2010.
60)  Shao H, Xi L, Raffeld M, Pittaluga S, Dunleavy K, Wilson WH, Spector N, Milito C, Morais JC, Jaffe ES.
Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression.
Am. J. Surg. Pathol. 34: 1425-35, 2010.
61)  O'Mahony D, Morris JC, Stetler-Stevenson M, Matthews H, Brown MR, Fleisher T, Pittaluga S, Raffeld M, Albert PS, Reitsma D, Kaucic K, Hammershaimb L, Waldmann TA, Janik JE.
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.
Clin. Cancer Res. 15: 2514-22, 2009.
62)  Wang Y, Digiovanna JJ, Stern JB, Hornyak TJ, Raffeld M, Khan SG, Oh KS, Hollander MC, Dennis PA, Kraemer KH.
Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.
Proc. Natl. Acad. Sci. U.S.A. 106: 6279-84, 2009.
63)  Stockwin LH, Vistica DT, Kenney S, Schrump DS, Butcher DO, Raffeld M, Shoemaker RH.
Gene expression profiling of alveolar soft-part sarcoma (ASPS).
BMC Cancer. 9: 22, 2009.
64)  Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G.
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Mol. Cancer Ther. 8: 1867-77, 2009.
65)  Killian JK, Bilke S, Davis S, Walker RL, Killian MS, Jaeger EB, Chen Y, Hipp J, Pittaluga S, Raffeld M, Cornelison R, Smith WI, Bibikova M, Fan JB, Emmert-Buck MR, Jaffe ES, Meltzer PS.
Large-scale profiling of archival lymph nodes reveals pervasive remodeling of the follicular lymphoma methylome.
Cancer Res. 69: 758-64, 2009.
66)  Tabe Y, Sebasigari D, Jin L, Rudelius M, Davies-Hill T, Miyake K, Miida T, Pittaluga S, Raffeld M.
MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
Clin. Cancer Res. 15: 933-42, 2009.
67)  Morovic A, Jaffe ES, Raffeld M, Schrager JA.
Metachronous EBV-associated B-cell and T-cell posttransplant lymphoproliferative disorders in a heart transplant recipient.
Am. J. Surg. Pathol. 33: 149-54, 2009.
68)  Alper O, Stetler-Stevenson WG, Harris LN, Leitner WW, Ozdemirli M, Hartmann D, Raffeld M, Abu-Asab M, Byers S, Zhuang Z, Oldfield EH, Tong Y, Bergmann-Leitner E, Criss WE, Nagasaki K, Mok SC, Cramer DW, Karaveli FS, Goldbach-Mansky R, Leo P, Stromberg K, Weil RJ.
Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.
Cancer Sci. 100: 1748-56, 2009.
69)  Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, Raffeld M, Janik JE, Prince HM, Bates SE.
Reactivation of DNA viruses in association with histone deacetylase inhibitor (HDI) therapy: a case series report.
Haematologica. 94: 1618-22, 2009.
70)  Vistica DT, Hollingshead M, Borgel SD, Kenney S, Stockwin LH, Raffeld M, Schrump DS, Burkett S, Stone G, Butcher DO, Shoemaker RH.
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.
J. Pediatr. Hematol. Oncol. 31: 561-70, 2009.
71)  Feldman AL, Arber DA, Pittaluga S, Martinez A, Burke JS, Raffeld M, Camos M, Warnke R, Jaffe ES.
Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone.
Blood. 111: 5433-9, 2008.
72)  Qi C, Li Z, Raffeld M, Wang H, Kovalchuk AL, Morse HC.
Differential expression of IRF8 in subsets of macrophages and dendritic cells and effects of IRF8 deficiency on splenic B cell and macrophage compartments.
Immunol. Res. 45: 62-74, 2008.
73)  Martinez A, Pittaluga S, Rudelius M, Davies-Hill T, Sebasigari D, Fountaine TJ, Hewitt S, Jaffe ES, Raffeld M.
Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker.
Am. J. Surg. Pathol. 32: 1190-200, 2008.
74)  Vistica DT, Krosky PM, Kenney S, Raffeld M, Shoemaker RH.
Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma.
J. Pediatr. Hematol. Oncol. 30: 46-52, 2008.
75)  Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE.
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
J. Clin. Oncol. 26: 2717-24, 2008.
76)  Mehta GU, Shively SB, Duong H, Tran MG, Moncrief TJ, Smith JH, Li J, Edwards NA, Lonser RR, Zhuang Z, Merrill MJ, Raffeld M, Maxwell PH, Oldfield EH, Vortmeyer AO.
Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease.
Neoplasia. 10: 1146-53, 2008.
77)  Shively SB, Beltaifa S, Gehrs B, Duong H, Smith J, Edwards NA, Lonser R, Raffeld M, Vortmeyer AO.
Protracted haemangioblastic proliferation and differentiation in von Hippel-Lindau disease.
J. Pathol. 216: 514-20, 2008.
78)  Kim RD, Greenberg DE, Ehrmantraut ME, Ding L, Shea Y, Chernick M, Jolley C, Raffeld M, Avila N, Sachdev V, Barnhart LA, Anderson VL, Claypool R, Fitzgerald A, Darnell D, Decastro R, Porcella SF, Olivier KN, Moss J, Holland SM.
Pulmonary Nontuberculous Mycobacterial Disease: Prospective Study of a Distinct Preexisting Syndrome.
Am. J. Respir. Crit. Care Med. 178: 1066-74, 2008.
79)  Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M, Fend F, Quintanilla-Martinez L.
Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2.
Leukemia. 22: 2097-105, 2008.
80)  Srivastava M, Torosyan Y, Raffeld M, Eidelman O, Pollard HB, Bubendorf L.
ANXA7 expression represents hormone-relevant tumor suppression in different cancers.
Int. J. Cancer. 121: 2628-36, 2007.
81)  Hardy NM, Grady C, Pentz R, Stetler-Stevenson M, Raffeld M, Fontaine LS, Babb R, Bishop MR, Caporaso N, Marti GE.
Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation.
Br. J. Haematol. 139: 824-31, 2007.
82)  Manosca F, Schinstine M, Fetsch PA, Sorbara L, Maria Wilder A, Brosky K, Erickson D, Raffeld M, Filie AC, Abati A.
Diagnostic effects of prolonged storage on fresh effusion samples.
Diagn. Cytopathol. 35: 6-11, 2007.
83)  Mao Z, Quintanilla-Martinez L, Raffeld M, Richter M, Krugmann J, Burek C, Hartmann E, Rudiger T, Jaffe ES, Müller-Hermelink HK, Ott G, Fend F, Rosenwald A.
IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
Am. J. Surg. Pathol. 31: 1605-14, 2007.
84)  Huang AM, Rudelius M, Sharan S, McAllister JM, Raffeld M, Christenson LK, Sterneck E.
The Cebpd (C/EBPdelta) gene is induced by luteinizing hormones in ovarian theca and interstitial cells but is not essential for mouse ovary function.
PLoS ONE. 2: e1334, 2007.
85)  Mehta GU, Shively SB, Gläsker S, Bechert CJ, Zhuang Z, Raffeld M, Lonser RR, Oldfield EH, Vortmeyer AO.
von Hippel-Lindau disease: epididymal cystadenoma targeted by metastatic events.
Urology. 69: 1209.e9-12, 2007.
86)  Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ, Weinstein JN.
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
Mol. Cancer Ther. 5: 2613-23, 2006.
87)  Arons E, Sorbara L, Raffeld M, Stetler-Stevenson M, Steinberg SM, Liewehr DJ, Pastan I, Kreitman RJ.
Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy.
Cancer Immunol. Immunother. 55: 1100-10, 2006.
88)  Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES, Quintanilla-Martinez L, Raffeld M.
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.
Blood. 108: 1668-76, 2006.
89)  Vortmeyer AO, Tran MG, Zeng W, Gläsker S, Riley C, Tsokos M, Ikejiri B, Merrill MJ, Raffeld M, Zhuang Z, Lonser RR, Maxwell PH, Oldfield EH.
Evolution of VHL tumourigenesis in nerve root tissue.
J. Pathol. 210: 374-82, 2006.
90)  Ahmed AA, Nava VE, Pham T, Taubenberger JK, Lichy JH, Sorbara L, Raffeld M, Mackall CL, Tsokos M.
Ewing sarcoma family of tumors in unusual sites: confirmation by rt-PCR.
Pediatr. Dev. Pathol. 9: 488-95, 2006.
91)  Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T.
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma.
J. Exp. Med. 203: 1235-47, 2006.
92)  Prakash S, Fountaine T, Raffeld M, Jaffe ES, Pittaluga S.
IgD positive L&H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma.
Am. J. Surg. Pathol. 30: 585-92, 2006.
93)  Arons E, Margulies I, Sorbara L, Raffeld M, Stetler-Stevenson M, Pastan I, Kreitman RJ.
Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.
Clin. Cancer Res. 12: 2804-11, 2006.
94)  Kobrin C, Cha SC, Qin H, Raffeld M, Fend F, Quintanilla-Martinez L, Grove S, Jaffe ES, Kwak LW.
Molecular analysis of light-chain switch and acute lymphoblastic leukemia transformation in two follicular lymphomas: implications for lymphomagenesis.
Leuk. Lymphoma. 47: 1523-34, 2006.
95)  Quintanilla-Martinez L, Pittaluga S, Miething C, Klier M, Rudelius M, Davies-Hill T, Anastasov N, Martinez A, Vivero A, Duyster J, Jaffe ES, Fend F, Raffeld M.
NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.
Blood. 108: 2029-36, 2006.
96)  Thangaraju M, Rudelius M, Bierie B, Raffeld M, Sharan S, Hennighausen L, Huang AM, Sterneck E.
C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution.
Development. 132: 4675-85, 2005.
97)  Feldman AL, Berthold F, Arceci RJ, Abramowsky C, Shehata BM, Mann KP, Lauer SJ, Pritchard J, Raffeld M, Jaffe ES.
Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis.
Lancet Oncol. 6: 435-7, 2005.
98)  Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B.
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
Cancer. 103: 2313-9, 2005.
99)  Schrager JA, Pittaluga S, Raffeld M, Jaffe ES.
Granulomatous reaction in Burkitt lymphoma: correlation with EBV positivity and clinical outcome.
Am. J. Surg. Pathol. 29: 1115-6, 2005.
100)  Maric I, Pittaluga S, Dale JK, Niemela JE, Delsol G, Diment J, Rosai J, Raffeld M, Puck JM, Straus SE, Jaffe ES.
Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome.
Am. J. Surg. Pathol. 29: 903-11, 2005.
101)  Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, Ito T, Venzon DJ, Serrano J, Jensen RT.
Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases.
Clin. Cancer Res. 11: 3233-42, 2005.
102)  Traverse-Glehen A, Pittaluga S, Gaulard P, Sorbara L, Alonso MA, Raffeld M, Jaffe ES.
Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.
Am. J. Surg. Pathol. 29: 1411-21, 2005.
103)  Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D.
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.
Am. J. Clin. Pathol. 124: 838-45, 2005.
104)  Gulmann C, Espina V, Petricoin E, Longo DL, Santi M, Knutsen T, Raffeld M, Jaffe ES, Liotta LA, Feldman AL.
Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma.
Clin. Cancer Res. 11: 5847-55, 2005.
105)  Zaragoza C, Li RM, Fahle GA, Fischer SH, Raffeld M, Lewis AM, Kopp JB.
Squirrel monkeys support replication of BK virus more efficiently than simian virus 40: an animal model for human BK virus infection.
J. Virol. 79: 1320-6, 2005.
106)  Guedez L, Martinez A, Zhao S, Vivero A, Pittaluga S, Stetler-Stevenson M, Raffeld M, Stetler-Stevenson WG.
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Blood. 105: 1660-8, 2005.
107)  Zu Y, Steinberg SM, Campo E, Hans CP, Weisenburger DD, Braziel RM, Delabie J, Gascoyne RD, Muller-Hermlink K, Pittaluga S, Raffeld M, Chan WC, Jaffe ES.
Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma.
Leuk. Lymphoma. 46: 693-701, 2005.
108)  Martinez A, Pittaluga S, Villamor N, Colomer D, Rozman M, Raffeld M, Montserrat E, Campo E, Jaffe ES.
Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients: clinicopathologic observations and molecular analysis.
Am. J. Surg. Pathol. 28: 849-58, 2004.
109)  Taylor ML, Sehgal D, Raffeld M, Obiakor H, Akin C, Mage RG, Metcalfe DD.
Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.
J Mol Diagn. 6: 335-42, 2004.
110)  Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, Jaffe ES, Grant N, Gutierrez M, Waldmann TA, Wilson WH.
Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.
Blood. 104: 3355-7, 2004.
111)  Feldman AL, Minniti C, Santi M, Downing JR, Raffeld M, Jaffe ES.
Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin.
Lancet Oncol. 5: 248-50, 2004.
112)  Maric I, Bryant R, Abu-Asab M, Cohen JI, Vivero A, Jaffe ES, Raffeld M, Tsokos M, Banks PM, Pittaluga S.
Human herpesvirus-6-associated acute lymphadenitis in immunocompetent adults.
Mod. Pathol. 17: 1427-33, 2004.
113)  Papadopoulos EJ, Jaffe ES, Elgart GW, Raffeld M, Turner ML.
Periodic fever with atypical dyshidrosis--quiz case.
Arch Dermatol. 140: 479-84, 2004.
114)  Kumar S, Pittaluga S, Raffeld M, Guerrera M, Seibel NL, Jaffe ES.
Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature.
Pediatr. Dev. Pathol. 8: 52-60, 2004.
115)  Srivastava M, Bubendorf L, Raffeld M, Bucher C, Torhorst J, Sauter G, Olsen C, Kallioniemi OP, Eidelman O, Pollard HB.
Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients.
Clin. Cancer Res. 10: 2344-50, 2004.
116)  Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E, Liotta LA, Jaffe ES.
Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray.
Lab. Invest. 84: 235-44, 2004.
117)  Mattu R, Sorbara L, Filie AC, Little R, Wilson W, Raffeld M, Abati A.
Utilization of polymerase chain reaction on archival cytologic material: a comparison with fresh material with special emphasis on cerebrospinal fluids.
Mod. Pathol. 17: 1295-301, 2004.
118)  Jaffe ES, Krenacs L, Raffeld M.
Classification of cytotoxic T-cell and natural killer cell lymphomas.
Semin Hematol. 40: 175-84, 2003.
119)  Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, Scherf U, Reinhold WC, Waltham M, Charboneau L, Young L, Bussey KJ, Kim S, Lababidi S, Lee JK, Pittaluga S, Scudiero DA, Sausville EA, Munson PJ, Petricoin EF, Liotta LA, Hewitt SM, Raffeld M, Weinstein JN.
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling.
Cancer Res. 63: 5243-50, 2003.
120)  Taddesse-Heath L, Feldman JI, Fahle GA, Fischer SH, Sorbara L, Raffeld M, Jaffe ES.
Florid CD4+, CD56+ T-cell infiltrate associated with Herpes simplex infection simulating nasal NK-/T-cell lymphoma.
Mod Pathol. 16: 166-72, 2003.
121)  Toro JR, Liewehr DJ, Pabby N, Sorbara L, Raffeld M, Steinberg SM, Jaffe ES.
Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma.
Blood. 101: 3407-12, 2003.
122)  Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, Wilson WH.
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Blood. 101: 4653-9, 2003.
123)  Bryant-Greenwood P, Sorbara L, Filie AC, Little R, Yarchoan R, Wilson W, Raffeld M, Abati A.
Infection of mesothelial cells with human herpes virus 8 in human immunodeficiency virus-infected patients with Kaposi's sarcoma, Castleman's disease, and recurrent pleural effusions.
Mod Pathol. 16: 145-53, 2003.
124)  Taddesse-Heath L, Pittaluga S, Sorbara L, Bussey M, Raffeld M, Jaffe ES.
Marginal zone B-cell lymphoma in children and young adults.
Am J Surg Pathol. 27: 522-31, 2003.
125)  Sausville JE, Salloum RG, Sorbara L, Kingma DW, Raffeld M, Kreitman RJ, Imus PD, Venzon D, Stetler-Stevenson M.
Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene.
Am J Clin Pathol. 119: 213-7, 2003.
126)  Barry TS, Jaffe ES, Sorbara L, Raffeld M, Pittaluga S.
Peripheral T-cell lymphomas expressing CD30 and CD15.
Am. J. Surg. Pathol. 27: 1513-22, 2003.
127)  Quintanilla-Martinez L, Davies-Hill T, Fend F, Calzada-Wack J, Sorbara L, Campo E, Jaffe ES, Raffeld M.
Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis.
Blood. 101: 3181-7, 2003.
128)  Jones MB, Michener CM, Blanchette JO, Kuznetsov VA, Raffeld M, Serrero G, Emmert-Buck MR, Petricoin EF, Krizman DB, Liotta LA, Kohn EC.
The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer.
Clin Cancer Res. 9: 44-51, 2003.
129)  Aerbajinai W, Giattina M, Lee YT, Raffeld M, Miller JL.
The proapoptotic factor Nix is coexpressed with Bcl-xL during terminal erythroid differentiation.
Blood. 102: 712-7, 2003.
130)  Krenacs L, Smyth MJ, Bagdi E, Krenacs T, Kopper L, Rudiger T, Zettl A, Muller-Hermelink HK, Jaffe ES, Raffeld M.
The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity.
Blood. 101: 3590-3, 2003.
131)  Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Blood. 101: 4944-51, 2003.
132)  Akin C, Jaffe ES, Raffeld M, Kirshenbaum AS, Daley T, Noel P, Metcalfe DD.
An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells.
Am J Clin Pathol. 118: 242-7, 2002.
133)  Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science. 298: 850-4, 2002.
134)  Barry TS, Jaffe ES, Kingma DW, Martin AW, Sorbara L, Raffeld M, Pittaluga S.
CD5+ follicular lymphoma: a clinicopathologic study of three cases.
Am J Clin Pathol. 118: 589-98, 2002.
135)  Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cornelison R, Goldberger N, Elkahloun AG, Willi N, Koivisto P, Ferhle W, Raffeld M, Sauter G, Kallioniemi OP.
Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays.
Cancer Res. 62: 1256-60, 2002.
136)  Fend F, Martinez A, Quintanilla-Martinez L, Sanz L, Combalia N, Raffeld M, Jaffe ES, Montserrat E, Campo E.
Clonally unrelated Hodgkin's disease following autologous stem cell transplant for B-cell lymphoma.
Br. J. Haematol. 116: 329-33, 2002.
137)  Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F.
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Blood. 99: 2685-93, 2002.
138)  Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J, Jensen RT.
Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness.
Cancer Res. 62: 3702-10, 2002.
139)  Cong P, Raffeld M, Teruya-Feldstein J, Sorbara L, Pittaluga S, Jaffe ES.
In situ localization of follicular lymphoma: description and analysis by laser capture microdissection.
Blood. 99: 3376-82, 2002.
140)  Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, Serrano J, Jensen RT.
Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability.
Clin Cancer Res. 8: 2273-85, 2002.
141)  Ahram M, Best CJ, Flaig MJ, Gillespie JW, Leiva IM, Chuaqui RF, Zhou G, Shu H, Duray PH, Linehan WM, Raffeld M, Ornstein DK, Zhao Y, Petricoin EF, Emmert-Buck MR.
Proteomic analysis of human prostate cancer.
Mol. Carcinog. 33: 9-15, 2002.
142)  Lim MS, Beaty M, Sorbara L, Cheng RZ, Pittaluga S, Raffeld M, Jaffe ES.
T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells.
Am J Surg Pathol. 26: 1458-66, 2002.
143)  Ishibe N, Prieto D, Hosack DA, Lempicki RA, Goldin LR, Raffeld M, Marti GE, Caporaso NE.
Telomere length and heavy-chain mutation status in familial chronic lymphocytic leukemia.
Leuk Res. 26: 791-4, 2002.
144)  Srivastava M, Bubendorf L, Nolan L, Glasman M, Leighton X, Miller G, Fehrle W, Raffeld M, Eidelman O, Kallioniemi OP, Srivastava S, Pollard HB.
ANX7 as a bio-marker in prostate and breast cancer progression.
Dis. Markers. 17: 115-20, 2001.
145)  Srivastava M, Bubendorf L, Srikantan V, Fossom L, Nolan L, Glasman M, Leighton X, Fehrle W, Pittaluga S, Raffeld M, Koivisto P, Willi N, Gasser TC, Kononen J, Sauter G, Kallioniemi OP, Srivastava S, Pollard HB.
ANX7, a candidate tumor suppressor gene for prostate cancer.
Proc. Natl. Acad. Sci. U.S.A. 98: 4575-80, 2001.
146)  Kuttler F, Amé P, Clark H, Haughey C, Mougin C, Cahn JY, Dang CV, Raffeld M, Fest T.
c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli.
Oncogene. 20: 6084-94, 2001.
147)  Njoroge JM, Mitchell LB, Centola M, Kastner D, Raffeld M, Miller JL.
Characterization of viable autofluorescent macrophages among cultured peripheral blood mononuclear cells.
Cytometry. 44: 38-44, 2001.
148)  Teruya-Feldstein J, Kingma DW, Weiss A, Sorbara L, Burd PR, Raffeld M, Mueller BU, Tosato G, Jaffe ES.
Chemokine gene expression and clonal analysis of B cells in tissues involved by lymphoid interstitial pneumonitis from HIV-infected pediatric patients.
Mod. Pathol. 14: 929-36, 2001.
149)  Beaty MW, Toro J, Sorbara L, Stern JB, Pittaluga S, Raffeld M, Wilson WH, Jaffe ES.
Cutaneous lymphomatoid granulomatosis: correlation of clinical and biologic features.
Am. J. Surg. Pathol. 25: 1111-20, 2001.
150)  Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Sauter G.
Gene-expression profiles in hereditary breast cancer.
N. Engl. J. Med. 344: 539-48, 2001.
151)  Lopatin U, Yao X, Williams RK, Bleesing JJ, Dale JK, Wong D, Teruya-Feldstein J, Fritz S, Morrow MR, Fuss I, Sneller MC, Raffeld M, Fleisher TA, Puck JM, Strober W, Jaffe ES, Straus SE.
Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression.
Blood. 97: 3161-70, 2001.
152)  Dagher R, Pham TA, Sorbara L, Kumar S, Long L, Bernstein D, Mackall C, Raffeld M, Tsokos M, Helman L.
Molecular confirmation of Ewing sarcoma.
J. Pediatr. Hematol. Oncol. 23: 221-4, 2001.
153)  Yao X, Teruya-Feldstein J, Raffeld M, Sorbara L, Jaffe ES.
Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall.
Mod. Pathol. 14: 105-10, 2001.
154)  Sarkodee-Adoo C, Pittarelli L, Jaffe E, Sorbara L, Raffeld M, Yao X, Haddad R, Heller T.
Regression and clonally distinct recurrence of human immunodeficiency virus related Burkitt-like lymphoma during antiretroviral therapy.
Leuk. Lymphoma. 42: 1125-31, 2001.
155)  Sakai A, Marti GE, Caporaso N, Pittaluga S, Touchman JW, Fend F, Raffeld M.
Analysis of expressed immunoglobulin heavy chain genes in familial B-CLL.
Blood. 95: 1413-9, 2000.
156)  Gutiérrez MI, Kingma DW, Sorbara L, Tran M, Raffeld M, Jaffe ES, Magrath I, Bhatia K.
Association of EBV strains, defined by multiple loci analyses, in non-Hodgkin lymphomas and reactive tissues from HIV positive and HIV negative patients.
Leuk Lymphoma. 37: 425-9, 2000.
157)  Fend F, Quintanilla-Martínez L, Raffeld M.
Composite lymphoma.
Hum Pathol. 31: 626-7, 2000.
158)  Wellmann A, Thieblemont C, Pittaluga S, Sakai A, Jaffe ES, Siebert P, Raffeld M.
Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas.
Blood. 96: 398-404, 2000.
159)  Yao L, Pike SE, Setsuda J, Parekh J, Gupta G, Raffeld M, Jaffe ES, Tosato G.
Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12.
Blood. 96: 1900-5, 2000.
160)  Kumar S, Fend F, Quintanilla-Martinez L, Kingma DW, Sorbara L, Raffeld M, Banks PM, Jaffe ES.
Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression.
Am J Surg Pathol. 24: 66-73, 2000.
161)  Goebel SU, Peghini PL, Goldsmith PK, Spiegel AM, Gibril F, Raffeld M, Jensen RT, Serrano J.
Expression of the calcium-sensing receptor in gastrinomas.
J. Clin. Endocrinol. Metab. 85: 4131-7, 2000.
162)  Quintanilla-Martinez L, Kumar S, Fend F, Reyes E, Teruya-Feldstein J, Kingma DW, Sorbara L, Raffeld M, Straus SE, Jaffe ES.
Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome.
Blood. 96: 443-51, 2000.
163)  Toro JR, Beaty M, Sorbara L, Turner ML, White J, Kingma DW, Raffeld M, Jaffe ES.
gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study.
Arch Dermatol. 136: 1024-32, 2000.
164)  Fend F, Raffeld M.
Laser capture microdissection in pathology.
J. Clin. Pathol. 53: 666-72, 2000.
165)  Lei JY, Wang Y, Jaffe ES, Turner ML, Raffeld M, Sorbara L, Morris J, Holland SM, Duray PH.
Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes simplex virus infection, and cutaneous T-cell lymphoma.
Am J Dermatopathol. 22: 524-9, 2000.
166)  Wilson WH, Sorbara L, Figg WD, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowicz AM, Monks A.
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Clin Cancer Res. 6: 415-21, 2000.
167)  Kumar S, Perlman E, Harris CA, Raffeld M, Tsokos M.
Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues.
Mod. Pathol. 13: 988-93, 2000.
168)  Beaty MW, Kumar S, Sorbara L, Miller K, Raffeld M, Jaffe ES.
A biophenotypic human herpesvirus 8--associated primary bowel lymphoma.
Am. J. Surg. Pathol. 23: 992-4, 1999.
169)  Thieblemont C, Pack S, Sakai A, Beaty M, Pak E, Vortmeyer AO, Wellmann A, Zhuang Z, Jaffe ES, Raffeld M.
Allelic loss of 11q13 as detected by MEN1-FISH is not associated with mutation of the MEN1 gene in lymphoid neoplasms.
Leukemia. 13: 85-91, 1999.
170)  Krenacs L, Krenacs T, Raffeld M.
Antigen retrieval for immunohistochemical reactions in routinely processed paraffin sections.
Methods Mol. Biol. 115: 85-93, 1999.
171)  Raffeld M, Jaffe ES.
Avidin-biotin labeling of cellular antigens in cryostat-sectioned tissue.
Methods Mol. Biol. 115: 215-22, 1999.
172)  Fend F, Quintanilla-Martinez L, Kumar S, Beaty MW, Blum L, Sorbara L, Jaffe ES, Raffeld M.
Composite low grade B-cell lymphomas with two immunophenotypically distinct cell populations are true biclonal lymphomas. A molecular analysis using laser capture microdissection.
Am. J. Pathol. 154: 1857-66, 1999.
173)  Cobo F, Hernández S, Hernández L, Pinyol M, Bosch F, Esteve J, López-Guillermo A, Palacín A, Raffeld M, Montserrat E, Jaffe ES, Campo E.
Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient.
J. Pathol. 189: 288-93, 1999.
174)  Jaffe ES, Krenacs L, Kumar S, Kingma DW, Raffeld M.
Extranodal peripheral T-cell and NK-cell neoplasms.
Am. J. Clin. Pathol. 111: S46-55, 1999.
175)  Quintanilla-Martinez L, Franklin JL, Guerrero I, Krenacs L, Naresh KN, Rama-Rao C, Bhatia K, Raffeld M, Magrath IT.
Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression.
Hum. Pathol. 30: 849-55, 1999.
176)  Fend F, Emmert-Buck MR, Chuaqui R, Cole K, Lee J, Liotta LA, Raffeld M.
Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis.
Am. J. Pathol. 154: 61-6, 1999.
177)  Kingma DW, Mueller BU, Frekko K, Sorbara LR, Wood LV, Katz D, Raffeld M, Jaffe ES.
Low-grade monoclonal Epstein-Barr virus-associated lymphoproliferative disorder of the brain presenting as human immunodeficiency virus-associated encephalopathy in a child with acquired immunodeficiency syndrome.
Arch. Pathol. Lab. Med. 123: 83-7, 1999.
178)  Fritsch M, Jaffe ES, Griffin C, Camacho J, Raffeld M, Kingma DW.
Lymphoproliferative disorder of fetal origin presenting as oligohydramnios.
Am. J. Surg. Pathol. 23: 595-601, 1999.
179)  Campo E, Raffeld M, Jaffe ES.
Mantle-cell lymphoma.
Semin. Hematol. 36: 115-27, 1999.
180)  Krenacs T, Krenacs L, Raffeld M.
Multiple antigen immunostaining procedures.
Methods Mol. Biol. 115: 223-33, 1999.
181)  Quintanilla-Martinez L, Fend F, Moguel LR, Spilove L, Beaty MW, Kingma DW, Raffeld M, Jaffe ES.
Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection.
Am. J. Surg. Pathol. 23: 1233-40, 1999.
182)  Finn LS, Viswanatha DS, Belasco JB, Snyder H, Huebner D, Sorbara L, Raffeld M, Jaffe ES, Salhany KE.
Primary follicular lymphoma of the testis in childhood.
Cancer. 85: 1626-35, 1999.
183)  Campo E, Miquel R, Krenacs L, Sorbara L, Raffeld M, Jaffe ES.
Primary nodal marginal zone lymphomas of splenic and MALT type.
Am. J. Surg. Pathol. 23: 59-68, 1999.
184)  Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, Krenacs L, Kingma DW, Raffeld M, Jaffe ES.
Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico.
Mod. Pathol. 11: 754-61, 1998.
185)  Gutiérrez MI, Spangler G, Kingma D, Raffeld M, Guerrero I, Misad O, Jaffe ES, Magrath IT, Bhatia K.
Epstein-Barr virus in nasal lymphomas contains multiple ongoing mutations in the EBNA-1 gene.
Blood. 92: 600-6, 1998.
186)  Teruya-Feldstein J, Zauber P, Setsuda JE, Berman EL, Sorbara L, Raffeld M, Tosato G, Jaffe ES.
Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and primary effusion lymphoma.
Lab. Invest. 78: 1637-42, 1998.
187)  Patel V, Senderowicz AM, Pinto D, Igishi T, Raffeld M, Quintanilla-Martinez L, Ensley JF, Sausville EA, Gutkind JS.
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
J. Clin. Invest. 102: 1674-81, 1998.
188)  Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M.
Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma.
Blood. 91: 4677-85, 1998.
189)  Quintanilla-Martinez L, Thieblemont C, Fend F, Kumar S, Pinyol M, Campo E, Jaffe ES, Raffeld M.
Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor.
Am. J. Pathol. 153: 175-82, 1998.
190)  Lim MS, Straus SE, Dale JK, Fleisher TA, Stetler-Stevenson M, Strober W, Sneller MC, Puck JM, Lenardo MJ, Elenitoba-Johnson KS, Lin AY, Raffeld M, Jaffe ES.
Pathological findings in human autoimmune lymphoproliferative syndrome.
Am. J. Pathol. 153: 1541-50, 1998.
191)  Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M.
PTEN gene alterations in lymphoid neoplasms.
Blood. 92: 3410-5, 1998.
192)  Kumar S, Krenacs L, Medeiros J, Elenitoba-Johnson KS, Greiner TC, Sorbara L, Kingma DW, Raffeld M, Jaffe ES.
Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes.
Hum. Pathol. 29: 397-403, 1998.
193)  Krenacs L, Himmelmann AW, Quintanilla-Martinez L, Fest T, Riva A, Wellmann A, Bagdi E, Kehrl JH, Jaffe ES, Raffeld M.
Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.
Blood. 92: 1308-16, 1998.
194)  Guo HG, Browning P, Nicholas J, Hayward GS, Tschachler E, Jiang YW, Sadowska M, Raffeld M, Colombini S, Gallo RC, Reitz MS.
Characterization of a chemokine receptor-related gene in human herpesvirus 8 and its expression in Kaposi's sarcoma.
Virology. 228: 371-8, 1997.
195)  Jaffe ES, Krenacs L, Raffeld M.
Classification of T-cell and NK-cell neoplasms based on the REAL classification.
Ann. Oncol. 8 Suppl 2: 17-24, 1997.
196)  Krenacs L, Wellmann A, Sorbara L, Himmelmann AW, Bagdi E, Jaffe ES, Raffeld M.
Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin.
Blood. 89: 980-9, 1997.
197)  Abruzzo LV, Griffith LM, Nandedkar M, Aguilera NS, Taubenberger JK, Raffeld M, Stass SA, Abbondanzo SL, Jaffe ES.
Histologically discordant lymphomas with B-cell and T-cell components.
Am. J. Clin. Pathol. 108: 316-23, 1997.
198)  Wellmann A, Krenacs L, Fest T, Scherf U, Pastan I, Raffeld M, Brinkmann U.
Localization of the cell proliferation and apoptosis-associated CAS protein in lymphoid neoplasms.
Am. J. Pathol. 150: 25-30, 1997.
199)  Elenitoba-Johnson KS, Kumar S, Lim MS, Kingma DW, Raffeld M, Jaffe ES.
Marginal zone B-cell lymphoma with monocytoid B-cell lymphocytes in pediatric patients without immunodeficiency. A report of two cases.
Am. J. Clin. Pathol. 107: 92-8, 1997.
200)  Mansoor A, Stevenson MS, Li RZ, Frekko K, Weiss W, Ahmad M, Khan AH, Mushtaq S, Saleem M, Raffeld M, Kingma DW, Jaffe ES.
Prevalence of Epstein-Barr viral sequences and EBV LMP1 oncogene deletions in Burkitt's lymphoma from Pakistan: epidemiological correlations.
Hum. Pathol. 28: 283-8, 1997.
201)  Kumar S, Kumar D, Kaldjian EP, Bauserman S, Raffeld M, Jaffe ES.
Primary low-grade B-cell lymphoma of the dura: a mucosa associated lymphoid tissue-type lymphoma.
Am. J. Surg. Pathol. 21: 81-7, 1997.
202)  Messineo C, Coupland R, Bakhshi A, Raffeld M, Irving SG, Bagg A, Cossman J.
Rearrangement, hypermutation, and possible preferential use of a VH5 gene, VH32, in a Hodgkin's cell line.
Hematopathol Mol Hematol. 11: 19-28, 1997.
203)  Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M.
Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas.
Blood. 89: 601-9, 1997.
204)  Wellmann A, Doseeva V, Butscher W, Raffeld M, Fukushima P, Stetler-Stevenson M, Gardner K.
The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts.
FASEB J. 11: 965-72, 1997.
205)  Sander CA, Kind P, Kaudewitz P, Raffeld M, Jaffe ES.
The Revised European-American Classification of Lymphoid Neoplasms (REAL): a new perspective for the classification of cutaneous lymphomas.
J. Cutan. Pathol. 24: 329-41, 1997.
206)  Otsuki T, Jaffe ES, Wellmann A, Kumar S, Condron KS, Raffeld M.
Absence of p18 mutations or deletions in lymphoid malignancies.
Leukemia. 10: 356-60, 1996.
207)  Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES.
Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b.
Blood. 87: 4531-7, 1996.
208)  Kumar S, Krenacs L, Otsuki T, Kumar D, Harris CA, Wellmann A, Jaffe ES, Raffeld M.
bc1-1 rearrangement and cyclin D1 protein expression in multiple lymphomatous polyposis.
Am. J. Clin. Pathol. 105: 737-43, 1996.
209)  Simon M, Kind P, Kaudewitz P, Graf A, Schirren CG, Raffeld M, Sander CA.
Detection of herpesvirus-like DNA in HIV-associated and classical Kaposi's sarcoma.
Arch. Dermatol. Res. 288: 402-4, 1996.
210)  Otsuki T, Kumar S, Ensoli B, Kingma DW, Yano T, Stetler-Stevenson M, Jaffe ES, Raffeld M.
Detection of HHV-8/KSHV DNA sequences in AIDS-associated extranodal lymphoid malignancies.
Leukemia. 10: 1358-62, 1996.
211)  Kingma DW, Shad A, Tsokos M, Fest T, Otsuki T, Frekko K, Werner E, Werner A, Magrath I, Raffeld M, Jaffe ES.
Epstein-Barr virus (EBV)-associated smooth-muscle tumor arising in a post-transplant patient treated successfully for two PT-EBV-associated large-cell lymphomas. Case report.
Am. J. Surg. Pathol. 20: 1511-9, 1996.
212)  Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeld M.
Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.
Blood. 88: 242-51, 1996.
213)  Cooke CB, Krenacs L, Stetler-Stevenson M, Greiner TC, Raffeld M, Kingma DW, Abruzzo L, Frantz C, Kaviani M, Jaffe ES.
Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin.
Blood. 88: 4265-74, 1996.
214)  Sander CA, Simon M, Puchta U, Raffeld M, Kind P.
HHV-8 in lymphoproliferative lesions in skin.
Lancet. 348: 475-6, 1996.
215)  Clark HM, Yano T, Sander C, Jaffe ES, Raffeld M.
Mutation of the ras genes is a rare genetic event in the histologic transformation of follicular lymphoma.
Leukemia. 10: 844-7, 1996.
216)  Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris MA, Montserrat E, Cardesa A, Jaffe ES, Campo E, Raffeld M.
p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas.
Blood. 87: 3351-9, 1996.
217)  Kumar S, Kingma DW, Weiss WB, Raffeld M, Jaffe ES.
Primary cutaneous Hodgkin's disease with evolution to systemic disease. Association with the Epstein-Barr virus.
Am. J. Surg. Pathol. 20: 754-9, 1996.
218)  Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M.
The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein.
Am. J. Pathol. 149: 143-51, 1996.
219)  Kumar S, Green GA, Teruya-Feldstein J, Raffeld M, Jaffe ES.
Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma.
Mod. Pathol. 9: 925-9, 1996.
220)  Wang J, Medeiros LJ, Longo DL, Mansoor A, Raffeld M, Duffey PL, Jaffe ES, Stetler-Stevenson M.
Use of the polymerase chain reaction technique to determine c-myc expression in follicular center cell lymphoma.
Diagn. Mol. Pathol. 5: 20-5, 1996.
221)  Hoang AT, Lutterbach B, Lewis BC, Yano T, Chou TY, Barrett JF, Raffeld M, Hann SR, Dang CV.
A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain.
Mol. Cell. Biol. 15: 4031-42, 1995.
222)  Otsuki T, Yano T, Clark HM, Bastard C, Kerckaert JP, Jaffe ES, Raffeld M.
Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences.
Blood. 85: 2877-84, 1995.
223)  Greiner TC, Raffeld M, Lutz C, Dick F, Jaffe ES.
Analysis of T cell receptor-gamma gene rearrangements by denaturing gradient gel electrophoresis of GC-clamped polymerase chain reaction products. Correlation with tumor-specific sequences.
Am. J. Pathol. 146: 46-55, 1995.
224)  Wellmann A, Otsuki T, Vogelbruch M, Clark HM, Jaffe ES, Raffeld M.
Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease.
Blood. 86: 2321-8, 1995.
225)  Raffeld M, Yano T, Hoang AT, Lewis B, Clark HM, Otsuki T, Dang CV.
Clustered mutations in the transcriptional activation domain of Myc in 8q24 translocated lymphomas and their functional consequences.
Curr. Top. Microbiol. Immunol. 194: 265-72, 1995.
226)  Kingma DW, Raffeld M, Jaffe ES.
Differential diagnosis of CD3+, CD56+ T-cell leukemias.
Blood. 85: 1675-6, 1995.
227)  Kolesnitchenko V, Wahl LM, Tian H, Sunila I, Tani Y, Hartmann DP, Cossman J, Raffeld M, Orenstein J, Samelson LE, Cohen DI.
Human immunodeficiency virus 1 envelope-initiated G2-phase programmed cell death.
Proc. Natl. Acad. Sci. U.S.A. 92: 11889-93, 1995.
228)  Otsuki T, Clark HM, Wellmann A, Jaffe ES, Raffeld M.
Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas.
Cancer Res. 55: 1436-40, 1995.
229)  Downing JR, Ladanyi M, Raffeld M, Weiss LM, Morris SW.
Large-cell anaplastic lymphoma-specific translocation in Hodgkin's disease.
Lancet. 345: 918; author reply 920-1, 1995.
230)  Teruya-Feldstein J, Temeck BK, Sloas MM, Kingma DW, Raffeld M, Pass HI, Mueller B, Jaffe ES.
Pulmonary malignant lymphoma of mucosa-associated lymphoid tissue (MALT) arising in a pediatric HIV-positive patient.
Am. J. Surg. Pathol. 19: 357-63, 1995.
231)  Whang-Peng J, Knutsen T, Jaffe ES, Steinberg SM, Raffeld M, Zhao WP, Duffey P, Condron K, Yano T, Longo DL.
Sequential analysis of 43 patients with non-Hodgkin's lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies.
Blood. 85: 203-16, 1995.
232)  Anwar N, Kingma DW, Bloch AR, Mourad M, Raffeld M, Franklin J, Magrath I, el Bolkainy N, Jaffe ES.
The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt: epidemiologic correlations.
Cancer. 76: 1245-52, 1995.
233)  Hollingsworth HC, Peiper SC, Weiss LM, Raffeld M, Jaffe ES.
An investigation of the viral pathogenesis of Kikuchi-Fujimoto disease. Lack of evidence for Epstein-Barr virus or human herpesvirus type 6 as the causative agents.
Arch. Pathol. Lab. Med. 118: 134-40, 1994.
234)  Raffeld M, Jaffe ES.
Avidin-biotin labeling of cellular antigens in cryostat-sectioned tissue.
Methods Mol. Biol. 34: 195-203, 1994.
235)  Ensoli B, Markham P, Kao V, Barillari G, Fiorelli V, Gendelman R, Raffeld M, Zon G, Gallo RC.
Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.
J. Clin. Invest. 94: 1736-46, 1994.
236)  Whang-Peng J, Knutsen T, Jaffe E, Raffeld M, Zhao WP, Duffey P, Longo DL.
Cytogenetic study of two cases with lymphoma of mucosa-associated lymphoid tissue.
Cancer Genet. Cytogenet. 77: 74-80, 1994.
237)  Longo DL, Duffey PL, Jaffe ES, Raffeld M, Hubbard SM, Fisher RI, Wittes RE, DeVita VT, Young RC.
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
J. Clin. Oncol. 12: 2153-9, 1994.
238)  Kingma DW, Medeiros LJ, Barletta J, Raffeld M, Mann RB, Ambinder RF, Jaffe ES.
Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Hodgkin's disease.
Am. J. Surg. Pathol. 18: 48-61, 1994.
239)  Hollingsworth HC, Stetler-Stevenson M, Gagneten D, Kingma DW, Raffeld M, Jaffe ES.
Immunodeficiency-associated malignant lymphoma. Three cases showing genotypic evidence of both T- and B-cell lineages.
Am. J. Surg. Pathol. 18: 1092-101, 1994.
240)  Clark HM, Yano T, Otsuki T, Jaffe ES, Shibata D, Raffeld M.
Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas.
Cancer Res. 54: 3383-6, 1994.
241)  Zarate-Osorno A, Raffeld M, Berman EL, Ferguson MM, Andrade R, Jaffe ES.
S-100-positive T-cell lymphoproliferative disorder. A case report and review of the literature.
Am. J. Clin. Pathol. 102: 478-82, 1994.
242)  Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, Cafaro A, Chang HK, Brady JN, Gallo RC.
Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma.
Nature. 371: 674-80, 1994.
243)  Jaffe ES, Zarate-Osorno A, Kingma DW, Raffeld M, Medeiros LJ.
The interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas.
Ann. Oncol. 5 Suppl 1: 7-11, 1994.
244)  Yano T, Sander CA, Clark HM, Dolezal MV, Jaffe ES, Raffeld M.
Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma.
Oncogene. 8: 2741-8, 1993.
245)  Wang J, Raffeld M, Medeiros LJ, Longo DL, Jaffe ES, Duffey P, Stetler-Stevenson M.
Follicular center cell lymphoma with the t(14;18) translocation in which the rearranged BCL-2 gene is silent.
Leukemia. 7: 1834-9, 1993.
246)  Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M.
p53 mutation is associated with progression in follicular lymphomas.
Blood. 82: 1994-2004, 1993.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/15/2013.